Angiogenesis Imaging of Adrenocortical Carcinoma with Ga-68-NODAGA-RGD Positron Emission Tomography: Opening New Horizons in Multimodality Imaging from Theranostic Perspective
Abstract
A 53-year-old female, with a known case of adrenocortical carcinoma (ACC), underwent F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for initial staging, which revealed FDG avid large left suprarenal mass contiguous with hypermetabolic tumor thrombus in the inferior vena cava (IVC) through the left renal vein. Thereafter, she underwent angiogenesis imaging using Ga-68-NODAGA-RGD PET/CT, which showed similar avid tracer uptake in both primary and IVC thrombus. Demonstration of RGD avidity in ACC in this case opens a new horizon for targeted radionuclide therapy (e.g., Lu-177 RGD) in selected patients, who may have limited therapeutic options.
Keywords: Adrenocortical carcinoma, F-18 fluorodeoxyglucose positron emission tomography/ computed tomography, Ga-68-NODAGA-RGD positron emission tomography/computed tomography, Lu-177 RGD
A 53-year-old female, a diagnosed case of adrenocortical carcinoma (ACC) was referred for F-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) for initial staging [Figure 1a whole-body maximum intensity projection (MIP) image, b and c axial coregistered PET/ CT images] which revealed a large well-defined heterogeneous left suprarenal mass with central hypodense necrotic areas (thick arrow in MIP image). The lesion measured 7.8 cm × 6.6 cm × 8.2 cm (AP × TR x CC) with an intense peripheral FDG uptake (SUVmax: 10.2) and a contiguous hypermetabolic thrombus (SUVmax: 7.9) that was infiltrating into the inferior vena cava (IVC) through the left renal vein up to the level of D-11 vertebra. Ga-68-NODAGA-RGD PET/CT in this patient showed avid uptake in the tumor with SUVmax of 18.55 (thin arrow in MIP) [Figure 1d whole-body MIP image, e and f axial coregistered PET/CT images]. Ga-68-NODAGA-RGD uptake was greater than the physiological uptake in the liver (7.79) and spleen (5.54). Additionally increased tracer uptake in the tumor thrombus was observed in IVC through the renal vein (SUVmax: 5.57). Figure 1g and h show contrast-enhanced CT images elucidating the left suprarenal mass with left renal and IVC invasion.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
ACC is a rare malignant neoplasm with a poor survival.[1,2] The majority of ACC is in the advanced stage at the time of presentation leading to poor prognosis.[3] Radical surgery of the primary tumor irrespective of the disease stage improves survival[4] even though patients operated at an earlier stage have better outcomes.[5] Therefore, early diagnosis and localization of metastases are critical in the management of ACC. F-18 FDG PET is useful in the detection of primary ACC and metastatic lesions.[6-9]
Oncologic imaging of angiogenesis with theranostic implications has been used for the evaluation of solid tumors including glioblastoma multiforme, squamous cell carcinoma of the head and neck, nonsmall cell lung cancer, breast cancer, melanoma, sarcoma, renal cancer, rectal cancer, and radioiodine refractory thyroid cancers with proven therapeutic benefit in the latter.[10-13]
Pereira et al. have shown that blood vessel density is increased in ACC, implying that angiogenesis could play an important role in the biologic behavior of these tumors.[14] As a corollary of the above, imaging using various radiolabeled derivatives of Arg- Gly-Asp (RGD) peptides, for example,
How to cite this article: Verma P, Chandak A, Shetye SS, Nazar AK, Bagul SD, Malhotra G. Angiogenesis imaging of adrenocortical carcinoma with Ga-68-NODAGA-RGD positron emission tomography: Opening new horizons in multimodality imaging from theranostic perspective. Indian J Nucl Med 2023;38:183-4.
Priyanka Verma1,2, Ashok Chandak1, Suyog Sharad Shetye3, Aamir K. Nazar1, Swati Dinesh Bagul1, Gaurav Malhotra1,2
1Radiation Medicine Centre, Bhabha Atomic Research Centre, 2Clinical Nuclear Medicine, Homi Bhabha National Institute, 3Department of Surgery, Seth G S Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India
Address for correspondence: Dr. Priyanka Verma, Radiation Medicine Centre, Bhabha Atomic Research Centre, TMC Annexe, Jerbai Wadia Road, Parel, Mumbai - 400 012, Maharashtra, India. E-mail: priyabsoni@gmail.com
Received: 17-11-2022 Accepted: 24-12-2022 Published: 08-06-2023
Access this article online
Website: www.ijnm.in
DOI: 10.4103/ijnm.ijnm_186_22
Quick Response Code:
b
e
g
a
c
d
f
h
Ga-68-NODAGA-RGD may be useful in functional imaging of angiogenesis in ACC as has been shown in the present case. Avid tracer uptake in both primary ACC and contiguous IVC tumor thrombus opens a new horizon for targeted alpha or beta emitters labeled RGD (e.g., Lu-177 RGD) therapy, which might be useful in selected patients (especially in those with inoperable and metastatic disease) in reducing the tumor burden and improving the quality of life. However, prospective studies with larger number of patients are required to validate our preliminary findings.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
1. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer 2008;113:3130-6.
2. Libé R. Adrenocortical carcinoma (ACC): Diagnosis, prognosis, and treatment. Front Cell Dev Biol 2015;3:45.
3. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004;60:273-87.
4. Tella SH, Kommalapati A, Yaturu S, Kebebew E. Predictors of survival in adrenocortical carcinoma: An analysis from the national cancer database. J Clin Endocrinol Metab 2018;103:3566-73.
5. Thomas SS, Marathe A, Cherian AJ, Siddhartha N, Mahasampath G, Therese MM, et al. Adrenocortical carcinoma: A therapeutic challenge - 44 cases from a single tertiary care center in India. Indian J Surg Oncol 2022;13:251-9.
6. Becherer A, Vierhapper H, Pötzi C, Karanikas G, Kurtaran A, Schmaljohann J, et al. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 2001;16:289-95.
7. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: Role of positron emission tomography. Endocr Rev 2004;25:568-80.
8. Groussin L, Bonardel G, Silvéra S, Tissier F, Coste J, Abiven G, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: A prospective study in 77 operated patients. J Clin Endocrinol Metab 2009;94:1713-22.
9. Deandreis D, Leboulleux S, Caramella C, Schlumberger M, Baudin E. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011;2:354-62.
10. Eo JS, Jeong JM. Angiogenesis imaging using (68) Ga-RGD PET/CT: Therapeutic implications. Semin Nucl Med 2016;46:419-27.
11. Niu G, Chen X. RGD PET: From lesion detection to therapy response monitoring. J Nucl Med 2016;57:501-2.
12. Parihar AS, Mittal BR, Kumar R, Shukla J, Bhattacharya A. (68) Ga-DOTA-RGD (2) positron emission tomography/computed tomography in radioiodine refractory thyroid cancer: Prospective comparison of diagnostic accuracy with (18) F-FDG positron emission tomography/computed tomography and evaluation toward potential theranostics. Thyroid 2020;30:557-67.
13. Parihar AS, Sood A, Kumar R, Bhusari P, Shukla J, Mittal BR. Novel use of (177) Lu-DOTA-RGD (2) in treatment of (68) Ga-DOTA-RGD (2)-avid lesions in papillary thyroid cancer with TENIS. Eur J Nucl Med Mol Imaging 2018;45:1836-7.
14. Pereira SS, Costa MM, Guerreiro SG, Monteiro MP, Pignatelli D. Angiogenesis and lymphangiogenesis in the adrenocortical tumors. Pathol Oncol Res 2018;24:689-93.